← 홈

HER2+ 유방암

465개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 465개
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab +Cetuximab β+Irinotecan)

HER2 Positive; Colorectal Cancer (CRC) · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab - intravenous solution)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Biosimilar ABP 980)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 79.4%임상시험 1상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Pyrotinib Exemestane Dalpiciclib)

Breast Cancer; Estrogen Receptor Positive Tumor · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab QW, Trastuzumab Q3W)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 9.5%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pyrotinib)

Advanced Breast Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

trastuzumab (Herceptin, Trastuzumab and non-pegylated liposomal doxorubicin)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#항체#면역항체+2
효능 ORR 33.3%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab combined with Pyrotinib and chemotherapy)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 71.7%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Trastuzumab plus chemotherapy)

HER2-positive Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+Nivolumab+Gemcitabine+Cisplatin)

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+Pertuzumab/Trastuzumab)

Breast Cancer; Adjuvant Therapy · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+pyrotinib+taxene)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs)

Metastatic Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC)

Biliary Tract Cancer (BTC); First-line Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC)

Biliary Tract Cancer (BTC); First-line Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Trastuzumab-rezetecan Treatment Group)

Trastuzumab-rezetecan; HER2-low Breast Cancer · HER2

#HER2#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 3.1%임상시험 1상태 ACTIVE
ADCBiologicstaleChia Tai Tianqing Pharmaceutica…Phase 3

Trifluridine /Tipiracil (TAS-102, Trifluridine /Tipiracil, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets)

HER2 IHC3+ Advanced Colorectal Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING

21 / 24 페이지

← 이전다음 →